JP2015525784A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015525784A5 JP2015525784A5 JP2015525632A JP2015525632A JP2015525784A5 JP 2015525784 A5 JP2015525784 A5 JP 2015525784A5 JP 2015525632 A JP2015525632 A JP 2015525632A JP 2015525632 A JP2015525632 A JP 2015525632A JP 2015525784 A5 JP2015525784 A5 JP 2015525784A5
- Authority
- JP
- Japan
- Prior art keywords
- vaccine
- vaccine according
- alkyl
- antigen
- fusion polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960005486 vaccine Drugs 0.000 claims 58
- 239000000427 antigen Substances 0.000 claims 23
- 102000036639 antigens Human genes 0.000 claims 23
- 108091007433 antigens Proteins 0.000 claims 23
- 201000008827 tuberculosis Diseases 0.000 claims 18
- 125000000217 alkyl group Chemical group 0.000 claims 16
- 208000015181 infectious disease Diseases 0.000 claims 15
- 230000004927 fusion Effects 0.000 claims 14
- 229920001184 polypeptide Polymers 0.000 claims 14
- 102000004196 processed proteins & peptides Human genes 0.000 claims 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims 14
- 208000036981 active tuberculosis Diseases 0.000 claims 12
- 241000124008 Mammalia Species 0.000 claims 9
- 241000186359 Mycobacterium Species 0.000 claims 6
- 239000002246 antineoplastic agent Substances 0.000 claims 6
- 229940127089 cytotoxic agent Drugs 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 241000187488 Mycobacterium sp. Species 0.000 claims 4
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims 4
- 239000002671 adjuvant Substances 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 241001467552 Mycobacterium bovis BCG Species 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000002685 pulmonary effect Effects 0.000 claims 2
- 238000010186 staining Methods 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 241000894006 Bacteria Species 0.000 claims 1
- 206010008479 Chest Pain Diseases 0.000 claims 1
- 206010011224 Cough Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 208000000616 Hemoptysis Diseases 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- 230000004596 appetite loss Effects 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 238000007821 culture assay Methods 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 229960003350 isoniazid Drugs 0.000 claims 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 claims 1
- 208000019017 loss of appetite Diseases 0.000 claims 1
- 235000021266 loss of appetite Nutrition 0.000 claims 1
- 210000003097 mucus Anatomy 0.000 claims 1
- 201000009671 multidrug-resistant tuberculosis Diseases 0.000 claims 1
- 206010029410 night sweats Diseases 0.000 claims 1
- 230000036565 night sweats Effects 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims 1
- 229960001225 rifampicin Drugs 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
- 208000016261 weight loss Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261679612P | 2012-08-03 | 2012-08-03 | |
| US61/679,612 | 2012-08-03 | ||
| US201361791213P | 2013-03-15 | 2013-03-15 | |
| US61/791,213 | 2013-03-15 | ||
| PCT/US2013/053482 WO2014042780A1 (en) | 2012-08-03 | 2013-08-02 | Compositions and methods for treating an active mycobacterium tuberculosis infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015525784A JP2015525784A (ja) | 2015-09-07 |
| JP2015525784A5 true JP2015525784A5 (enExample) | 2016-09-23 |
Family
ID=50278593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015525632A Pending JP2015525784A (ja) | 2012-08-03 | 2013-08-02 | 活動性結核菌感染を治療するための組成物及び方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20150182612A1 (enExample) |
| EP (2) | EP4299138A3 (enExample) |
| JP (1) | JP2015525784A (enExample) |
| CN (1) | CN104812404A (enExample) |
| BR (1) | BR112015002483A2 (enExample) |
| ES (1) | ES2969734T3 (enExample) |
| HR (1) | HRP20240164T1 (enExample) |
| HU (1) | HUE065746T2 (enExample) |
| MX (1) | MX385774B (enExample) |
| PT (1) | PT2879701T (enExample) |
| RU (1) | RU2659149C2 (enExample) |
| WO (1) | WO2014042780A1 (enExample) |
| ZA (2) | ZA201501242B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3458088A2 (en) * | 2016-05-21 | 2019-03-27 | Infectious Disease Research Institute | Compositions and methods for treating secondary tuberculosis and nontuberculous mycobacterium infections |
| GB201909953D0 (en) * | 2019-07-11 | 2019-08-28 | Sec Dep For Environment Food And Rural Affairs Acting Through The Animal And Plant Health Agency | Diagnostic reagents |
| WO2021194672A1 (en) | 2020-03-23 | 2021-09-30 | Hdt Bio Corp. | Compositions and methods for delivery of rna |
| US11679163B2 (en) | 2019-09-20 | 2023-06-20 | Hdt Bio Corp. | Compositions and methods for delivery of RNA |
| JP2024501949A (ja) | 2020-12-23 | 2024-01-17 | アクセス ツー アドバンスト ヘルス インスティチュート | ソラネソールワクチンアジュバント及びその調製方法 |
| CA3232658A1 (en) | 2021-09-22 | 2023-03-30 | Steven Gregory REED | Rna vaccines against infectious diseases |
| AU2022352486A1 (en) | 2021-09-22 | 2024-04-11 | Hdt Bio Corp. | Dried nanoparticle compositions |
| WO2023049636A2 (en) | 2021-09-22 | 2023-03-30 | Hdt Bio Corp. | Cancer therapy compositions and uses thereof |
| JP2024535352A (ja) | 2021-09-22 | 2024-09-30 | エイチディーティー バイオ コーポレーション | Ｓａｒｓ－ｃｏｖ－２ ｒｎａワクチン組成物および使用方法 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
| US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| US5725871A (en) | 1989-08-18 | 1998-03-10 | Danbiosyst Uk Limited | Drug delivery compositions comprising lysophosphoglycerolipid |
| US5707644A (en) | 1989-11-04 | 1998-01-13 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
| US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
| SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
| US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| US5756353A (en) | 1991-12-17 | 1998-05-26 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol-and liposome-based delivery |
| ATE155681T1 (de) | 1992-05-18 | 1997-08-15 | Minnesota Mining & Mfg | Einrichtung zur transmucosalen wirkstoffabgabe |
| DE69313134T2 (de) | 1992-06-25 | 1998-02-26 | Smithkline Beecham Biolog | Adjuvantien enthaltende impfstoffzusammensetzung |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| AU713040B2 (en) | 1994-07-15 | 1999-11-18 | University Of Iowa Research Foundation, The | Immunomodulatory oligonucleotides |
| IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| US5856462A (en) | 1996-09-10 | 1999-01-05 | Hybridon Incorporated | Oligonucleotides having modified CpG dinucleosides |
| GB9727262D0 (en) | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
| BR9909915A (pt) | 1998-04-09 | 2000-12-26 | Smithkline Beecham Biolog | Composições adjuvantes |
| ATE315405T1 (de) | 1998-08-10 | 2006-02-15 | Antigenics Inc | Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung |
| US7472098B2 (en) | 2000-02-14 | 2008-12-30 | Ubs Financial Services, Inc. | System and method for execution of trades made pursuant to stock option and purchase plans |
| RU2262950C2 (ru) * | 2001-03-23 | 2005-10-27 | Каунсил Оф Сайентифик Энд Индастриал Рисерч | Способ получения вакцины для лечения туберкулеза и других внутриклеточных инфекционных заболеваний и вакцина, полученная по названному способу |
| GB0125535D0 (en) * | 2001-10-24 | 2001-12-12 | Microbiological Res Authority | Mycobacterial genes down-regulated during latency |
| PT2426141E (pt) * | 2005-04-29 | 2014-11-25 | Glaxosmithkline Biolog Sa | Método para prevenção ou tratamento de uma infecção por m. tuberculosis |
| EP1991213A2 (en) * | 2006-02-08 | 2008-11-19 | Fasgen, Inc. | Anti-mycobacterial formulation comprising octanesulphonylacetamide (osa), nonanesulphonylacetamide (nsa) and decanesulphonylacetamide (dsa) |
| EP2468300B1 (en) | 2006-09-26 | 2017-12-20 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
| WO2008124647A2 (en) * | 2007-04-04 | 2008-10-16 | Infectious Disease Research Institute | Immunogenic compositions comprising mycobacterium tuberculosis polypeptides and fusions thereof |
| WO2010010178A1 (en) * | 2008-07-25 | 2010-01-28 | Glaxosmithkline Biologicals S.A | The tuberculosis rv2707c protein, compositions and uses thereof |
| EP2353008A2 (en) * | 2008-09-22 | 2011-08-10 | Oregon Health and Science University | Methods for detecting a mycobacterium tuberculosis infection |
| GB201008512D0 (en) * | 2010-05-21 | 2010-07-07 | Health Prot Agency | Mycobacterial antigen composition |
| CA2808556A1 (en) * | 2010-09-20 | 2012-03-29 | Crucell Holland B.V. | Therapeutic vaccination against active tuberculosis |
-
2013
- 2013-08-02 EP EP23206775.1A patent/EP4299138A3/en active Pending
- 2013-08-02 BR BR112015002483A patent/BR112015002483A2/pt not_active Application Discontinuation
- 2013-08-02 CN CN201380051732.7A patent/CN104812404A/zh active Pending
- 2013-08-02 HU HUE13836324A patent/HUE065746T2/hu unknown
- 2013-08-02 RU RU2015107435A patent/RU2659149C2/ru active
- 2013-08-02 WO PCT/US2013/053482 patent/WO2014042780A1/en not_active Ceased
- 2013-08-02 US US14/419,477 patent/US20150182612A1/en not_active Abandoned
- 2013-08-02 MX MX2015001557A patent/MX385774B/es unknown
- 2013-08-02 HR HRP20240164TT patent/HRP20240164T1/hr unknown
- 2013-08-02 EP EP13836324.7A patent/EP2879701B1/en active Active
- 2013-08-02 JP JP2015525632A patent/JP2015525784A/ja active Pending
- 2013-08-02 PT PT138363247T patent/PT2879701T/pt unknown
- 2013-08-02 ES ES13836324T patent/ES2969734T3/es active Active
-
2015
- 2015-02-24 ZA ZA2015/01242A patent/ZA201501242B/en unknown
-
2017
- 2017-03-24 ZA ZA2017/02091A patent/ZA201702091B/en unknown
-
2018
- 2018-09-10 US US16/126,285 patent/US11369672B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lin et al. | CD8 T cells and Mycobacterium tuberculosis infection | |
| RU2015107435A (ru) | Композиции и способы для лечения активной инфекции mycobacterium tuberculosis | |
| US8741313B2 (en) | Polypeptide vaccine and vaccination strategy against mycobacterium | |
| US11014969B2 (en) | Tuberculosis compositions and methods of using the same | |
| Ma et al. | Mycobacterium tuberculosis multistage antigens confer comprehensive protection against pre-and post-exposure infections by driving Th1-type T cell immunity | |
| RU2019130941A (ru) | РЕКОМБИНАНТНАЯ BCG, СВЕРХЭКСПРЕССИРУЮЩАЯ PhoP-PhoR | |
| CN101600455A (zh) | 预防性结核疫苗 | |
| JP6229080B2 (ja) | 新規な温度敏感性マイコバクテリア菌株を含むマイコバクテリア感染症に対するワクチン組成物 | |
| Cai et al. | Combined DNA vaccines formulated either in DDA or in saline protect cattle from Mycobacterium bovis infection | |
| Li et al. | Threshold level of Riemerella anatipestifer crossing blood-brain barrier and expression profiles of immune-related proteins in blood and brain tissue from infected ducks | |
| Deng et al. | Evaluation of protective efficacy conferred by a recombinant Mycobacterium bovis BCG expressing a fusion protein of Ag85A-ESAT-6 | |
| Heller et al. | Characterization of Brucella abortus infection of bovine monocyte-derived dendritic cells | |
| CN103266119A (zh) | 一种结核杆菌三抗原融合基因疫苗及其制备方法和应用 | |
| Deng et al. | Evaluation of immunogenicity and protective efficacy against Mycobacterium tuberculosis infection elicited by recombinant Mycobacterium bovis BCG expressing human Interleukin‐12p70 and Early Secretory Antigen Target‐6 fusion protein | |
| Roche et al. | Vaccination with DNA of the Mycobacterium tuberculosis 85B antigen protects mouse foot pad against infection with M. leprae | |
| CN102247595B (zh) | 一种聚肌胞联合二甲基三十六烷基铵混合佐剂在制备结核亚单位疫苗中的应用 | |
| CN106148258A (zh) | mazG基因缺失的抗结核重组卡介苗 | |
| JPWO2013039069A1 (ja) | 新規な組換えｂｃｇワクチン | |
| Camussone et al. | Immune response and functional role of antibodies raised in heifers against a Staphylococcus aureus CP5 lysate and recombinant antigens vaccine formulated with Iscom Matrix adjuvant | |
| KR101624208B1 (ko) | Ｒｖ０３５１ 단백질을 포함하는 결핵 예방용 백신 조성물 | |
| Ji et al. | Boosting BCG-primed mice with chimeric DNA vaccine HG856A induces potent multifunctional T cell responses and enhanced protection against Mycobacterium tuberculosis | |
| Nyasulu | The role of adjunctive Mycobacterium w immunotherapy for tuberculosis | |
| JPWO2002066055A1 (ja) | α抗原またはα抗原遺伝子の新規医薬用途 | |
| JP2016101124A (ja) | 結核ワクチン | |
| CA2598078A1 (en) | Compositions for eliciting an immune response against mycobacterium avium subspecies paratuberculosis |